EGFR and lung adenocarcinoma: Furthermore, a report performed by Masuda et al. [24] showed clinical improvements following the change to erlotinib therapy in lung adenocarcinoma patients with EGFR mutations who developed leptomeningeal metastases during gefitinib therapy.